-
Published02/12/2024
-
Today25/01/2025
-
Deadline31/12/2026
Utilities
- indicates text translated automatically in your browsing language
Conclusion of non-exclusive discount agreements pursuant to § 130a(8) SGB V on the above-mentioned active substances with the possibility of conclusion within the framework of the so-called open-house procedure. Text automatically translated in your browsing language Automatically translated
The Kaufmännische Krankenkasse - KKH (hereinafter referred to as KKH) pursues the objective of concluding discount agreements with all suitable pharmaceutical companies in accordance with § 130a(8) SGB V on the active substance(s) within the framework of a so-called "open-house procedure". Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or accession to a discount contract pursuant to § 130a(8) SGB V for the active substance specified in the invitation to tender. Interested pharmaceutical companies can request the participation documents and the contract from the above-mentioned contact address (rabattvertraege@kkh.de). Text automatically translated in your browsing language Automatically translated
https://www.kkh.de/vertragspartner/arzneimittel
https://www.kkh.de/vertragspartner/arzneimittel
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.